CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly desmoplastic and immunosuppressive tumor microenvironment (TME) that limits immune-cell infiltration, impairs antigen presentation, and promotes tumor-supportive myeloid responses. CD40 agonism offers a distinct immunotherapeutic strategy by activating macrophages and antigen-presenting cells (APCs), enhancing antigen presentation, and promoting innate and adaptive antitumor immunity. Preclinical studies have demonstrated macrophage-dependent tumor regression and stromal remodeling, while combination with chemotherapy can enhance antigen release and subsequent immune priming. Clinical studies of CD40 agonists, including sotigalimab, mitazalimab, and selicrelumab, have demonstrated immune and TME remodeling, but consistent survival benefit has not been established in unselected patients. Differences in treatment context, chemotherapy backbone, treatment sequence, and antibody architecture may contribute to variable clinical outcomes. Emerging evidence indicates that limited therapeutic activity may reflect multiple factors, including APC deficiency, persistent immunosuppression, inadequate effector responses, stromal and spatial immune exclusion, and pharmacologic limitations related to Fcγ receptor engagement and systemic toxicity. Future development should therefore emphasize biomarker-guided patient selection, rational treatment sequencing, spatially controlled CD40 activation, and mechanistically matched combination strategies. Integration of immune, molecular, and pharmacodynamic biomarkers, together with next-generation CD40 agonists, may help translate CD40-mediated immune remodeling into more durable clinical benefit in PDAC.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210329
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation

Won Sup Lee, Se‐Il Go, Myoung Hee Kang
5 links
International Journal of Molecular Sciences
Pancreatic and Hepatic Oncology Research
article

CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation

Won Sup Lee, Se‐Il Go, Myoung Hee Kang
article en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly desmoplastic and immunosuppressive tumor microenvironment (TME) that limits immune-cell infiltration, impairs antigen presentation, and promotes tumor-supportive myeloid responses. CD40 agonism offers a distinct immunotherapeutic strategy by activating macrophages and antigen-presenting cells (APCs), enhancing antigen presentation, and promoting innate and adaptive antitumor immunity. Preclinical studies have demonstrated macrophage-dependent tumor regression and stromal remodeling, while combination with chemotherapy can enhance antigen release and subsequent immune priming. Clinical studies of CD40 agonists, including sotigalimab, mitazalimab, and selicrelumab, have demonstrated immune and TME remodeling, but consistent survival benefit has not been established in unselected patients. Differences in treatment context, chemotherapy backbone, treatment sequence, and antibody architecture may contribute to variable clinical outcomes. Emerging evidence indicates that limited therapeutic activity may reflect multiple factors, including APC deficiency, persistent immunosuppression, inadequate effector responses, stromal and spatial immune exclusion, and pharmacologic limitations related to Fcγ receptor engagement and systemic toxicity. Future development should therefore emphasize biomarker-guided patient selection, rational treatment sequencing, spatially controlled CD40 activation, and mechanistically matched combination strategies. Integration of immune, molecular, and pharmacodynamic biomarkers, together with next-generation CD40 agonists, may help translate CD40-mediated immune remodeling into more durable clinical benefit in PDAC.

International Journal of Molecular SciencesVol. 27(22)
Gyeongsang National University (KR), Gyeongsang National University Hospital (KR), Gyeongsang National University Changwon Hospital (KR)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon